For Chronic Wounds

The patient population that suffers from chronic wounds may benefit from the cell therapies of PermaDerm® and other products being developed by Regenicin™. Because the cells are regenerated from the patient’s own skin, the possibility of immune system rejection is expected to be significantly reduced when used to treat the wound. The regenerated, cultured skin is composed of both an epidermal and dermal barrier, which is expected to help the wound to close quickly, greatly reducing complications.